Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs
Condition: Systemic Lupus Erythematosus Intervention: Other: None (Observational study) Sponsors: AstraZeneca; CernerEnviza Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation
Condition: BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Intervention: Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting Sponsors: Assistance Publique - Hôpitaux de Paris; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs
Condition: Systemic Lupus Erythematosus Intervention: Other: None (Observational study) Sponsors: AstraZeneca; CernerEnviza Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation
Condition: BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Intervention: Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting Sponsors: Assistance Publique - Hôpitaux de Paris; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs
Condition: Systemic Lupus Erythematosus Intervention: Other: None (Observational study) Sponsors: AstraZeneca; CernerEnviza Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation
Condition: BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Intervention: Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting Sponsors: Assistance Publique - Hôpitaux de Paris; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs
Condition: Systemic Lupus Erythematosus Intervention: Other: None (Observational study) Sponsors: AstraZeneca; CernerEnviza Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation
Condition: BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Intervention: Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting Sponsors: Assistance Publique - Hôpitaux de Paris; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs
Condition: Systemic Lupus Erythematosus Intervention: Other: None (Observational study) Sponsors: AstraZeneca; CernerEnviza Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation
Conditions: BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Interventions: Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting Sponsors: Assistance Publique - H ôpitaux de Paris; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
